Dr. Forster on Next Steps With Lurbinectedin in SCLC

Video

Martin Forster, MD, a medical oncologist, University College London Hospitals, discusses the next steps with the investigational agent lurbinectedin in combination with doxorubicin as a second-line therapy for patients with small cell lung cancer (SCLC).

Martin Forster, MD, a medical oncologist, University College London Hospitals, discusses the next steps with the investigational agent lurbinectedin in combination with doxorubicin as a second-line therapy for patients with small cell lung cancer (SCLC).

In a multicenter, phase Ib, 3+3 dose-escalation study, data presented at the 2018 World Conference on Lung Cancer showed longer follow-up from a data set looking at the progression-free and overall survival of lurbinectedin plus doxorubicin. The preliminary data from this early-phase trial led to the development of the phase III ATLANTIS study, which is now closed to recruitment. The study is investigating lurbinectedin with doxorubicin versus investigator’s choice of either cyclophosphamide, doxorubicin and vincristine or topotecan. Results are anticipated sometime in early 2019, Forster says.

The world of clinical trials and management of lung cancer is rapidly changing with the evolving role of immunotherapy, making the development of other agents quite difficult, he adds. This is especially true since the standard of care continues to change. A challenge is setting the role of lurbinectedin in these changing standards. However, the role of immunotherapy has been less promising in the second-line setting, he concludes. Therefore, this could position lurbinectedin nicely in the second-line setting.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.